|drug751||Choices and judgements Wiki||1.00|
|drug581||COVID visitation restrictions Wiki||1.00|
|D006331||Heart Diseases NIH||0.38|
|D006333||Heart Failure NIH||0.35|
There is one clinical trial.
Patients are part of a family network. When any person in a family becomes critically unwell and requires the assistance of an Intensive Care Unit (ICU), this has an impact on all members of that family. COVID-19 changed visiting for all patients in hospitals across Scotland. It is not known what effect these restrictions will have on patients' recovery, nor do we understand the impact it may have on their relatives or staff caring for them. This study will look at the implications of the visiting restrictions as a consequence of the COVID-19 pandemic upon patients without COVID-19 who are in the cardiothoracic ICU. It will also explore the impact of these restrictions on them, their relatives and staff. This study will be carried out within a single specialised intensive care unit in Scotland using mixed methods. The first arm of this study will use retrospective data that is routinely collected in normal clinical practice. The investigators will compare patient outcomes prior to COVID-19 with outcomes following the implementation of COVID-19 visiting restrictions. The aim is to establish if the restrictions on visiting has an impact on the duration of delirium. Delirium is an acute mental confusion and is associated with longer hospital stays and worse outcomes in this patient group. The second arm of this study involves semi-structured interviews with patients, relatives and staff that will allow deeper exploration of the issues around current visiting policy. The interviews will last approximately 1 hour and will address these issues. They will then be transcribed word for word and analysed using grounded theory, meaning the theories will develop from the data as it is analysed.
Description: Number of days patient found to have delirium using the Confusion Assessment Method for the ICU (CAM-ICU)Measure: Duration of delirium Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.
Description: CAM-ICUMeasure: Incidence of delirium Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.
Description: DaysMeasure: Length of critical care stay Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.
Description: DaysMeasure: Length of hospital stay Time: From the date of admission to the hospital until discharge from the hospital or death, whichever came first, up to 12 months.
Description: DaysMeasure: Length of time ventilated Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.
Description: Semi structured interviewsMeasure: Exploring the experiences of patients, relatives and staff of the visitation restrictions during the COVID-19 pandemic Time: 18 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports